These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 21047299)
21. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration. Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404 [TBL] [Abstract][Full Text] [Related]
22. Adverse drug event reporting in intensive care units: a survey of current practices. Kane-Gill SL; Devlin JW Ann Pharmacother; 2006; 40(7-8):1267-73. PubMed ID: 16849619 [TBL] [Abstract][Full Text] [Related]
23. Adverse drug event reporting systems: a systematic review. Bailey C; Peddie D; Wickham ME; Badke K; Small SS; Doyle-Waters MM; Balka E; Hohl CM Br J Clin Pharmacol; 2016 Jul; 82(1):17-29. PubMed ID: 27016266 [TBL] [Abstract][Full Text] [Related]
24. Development of a 'ready-to-use' tool that includes preventability, for the assessment of adverse drug events in oncology. Hébert G; Netzer F; Kouakou SL; Lemare F; Minvielle E; Int J Clin Pharm; 2018 Apr; 40(2):376-385. PubMed ID: 29446003 [TBL] [Abstract][Full Text] [Related]
25. Effect of the black triangle scheme and its online educational campaign on the quantity and quality of adverse drug event reporting in Australia: a time series analysis. Li R; Curtis K; Zaidi STR; Van C; Castelino R Expert Opin Drug Saf; 2020 Jun; 19(6):747-753. PubMed ID: 32207361 [TBL] [Abstract][Full Text] [Related]
26. Documentation of penicillin adverse drug reactions in electronic health records: inconsistent use of allergy and intolerance labels. Inglis JM; Caughey GE; Smith W; Shakib S Intern Med J; 2017 Nov; 47(11):1292-1297. PubMed ID: 28742226 [TBL] [Abstract][Full Text] [Related]
27. The quality of published adverse drug event reports. Kelly WN Ann Pharmacother; 2003 Dec; 37(12):1774-8. PubMed ID: 14632590 [TBL] [Abstract][Full Text] [Related]
28. Use of a Bioinformatics-Based Toxicity Scoring System to Assess Serotonin Burden and Predict Population-Level Adverse Drug Events from Concomitant Serotonergic Drug Therapy. Culbertson VL; Rahman SE; Bosen GC; Caylor ML; Xu D Pharmacotherapy; 2019 Feb; 39(2):171-181. PubMed ID: 30620414 [TBL] [Abstract][Full Text] [Related]
29. ADE Eval: An Evaluation of Text Processing Systems for Adverse Event Extraction from Drug Labels for Pharmacovigilance. Bayer S; Clark C; Dang O; Aberdeen J; Brajovic S; Swank K; Hirschman L; Ball R Drug Saf; 2021 Jan; 44(1):83-94. PubMed ID: 33006728 [TBL] [Abstract][Full Text] [Related]
30. Evaluating iatrogenic prescribing: development of an oncology-focused trigger tool. Hébert G; Netzer F; Ferrua M; Ducreux M; Lemare F; Minvielle E Eur J Cancer; 2015 Feb; 51(3):427-35. PubMed ID: 25549531 [TBL] [Abstract][Full Text] [Related]
31. Perceived barriers to reporting adverse drug events in hospitals: a qualitative study using theoretical domains framework approach. Mirbaha F; Shalviri G; Yazdizadeh B; Gholami K; Majdzadeh R Implement Sci; 2015 Aug; 10():110. PubMed ID: 26250159 [TBL] [Abstract][Full Text] [Related]
32. Examination of pharmacists' intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior. Gavaza P; Brown CM; Lawson KA; Rascati KL; Wilson JP; Steinhardt M Res Social Adm Pharm; 2011 Dec; 7(4):369-82. PubMed ID: 21272531 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology. Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093 [TBL] [Abstract][Full Text] [Related]
34. Texas pharmacists' knowledge of reporting serious adverse drug events to the Food and Drug Administration. Gavaza P; Brown CM; Lawson KA; Rascati KL; Wilson JP; Steinhardt M J Am Pharm Assoc (2003); 2011; 51(3):397-403. PubMed ID: 21555292 [TBL] [Abstract][Full Text] [Related]
35. Inter-rater reliability of a classification system for hospital adverse drug event reports. Haynes K; Hennessy S; Morales KH; Gibson GA; Barnhart C; Jaipaul CK; Linkin DR Clin Pharmacol Ther; 2008 Mar; 83(3):485-8. PubMed ID: 17713472 [TBL] [Abstract][Full Text] [Related]
36. Identifying Medication-Related Adverse Drug Events in Nursing Facilities in East Texas. Tenhunen ML; Smithers B; Tucker B Consult Pharm; 2016; 31(8):436-9. PubMed ID: 27535078 [TBL] [Abstract][Full Text] [Related]
37. Consistency in the safety labeling of bioequivalent medications. Duke J; Friedlin J; Li X Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584 [TBL] [Abstract][Full Text] [Related]
38. Texas pharmacists' opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study. Gavaza P; Brown CM; Khoza S Pharm World Sci; 2010 Oct; 32(5):651-7. PubMed ID: 20652830 [TBL] [Abstract][Full Text] [Related]
39. SSEL-ADE: A semi-supervised ensemble learning framework for extracting adverse drug events from social media. Liu J; Zhao S; Wang G Artif Intell Med; 2018 Jan; 84():34-49. PubMed ID: 29111222 [TBL] [Abstract][Full Text] [Related]
40. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. Tamma PD; Avdic E; Li DX; Dzintars K; Cosgrove SE JAMA Intern Med; 2017 Sep; 177(9):1308-1315. PubMed ID: 28604925 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]